← Human Trials & Peer-Reviewed Studies

Ghrelin and obestatin in human neuroendocrine tumors: expression and effect on obestatin levels after food intake

Plain-language guide to PMID 23147274 (2013): controlled clinical trial study of Ghrelin in 6 individuals.

Key Facts

PMID
23147274
Journal
Neuroendocrinology
Year
2013
Study type
Controlled Clinical Trial
Authors
Grönberg M et al. (6 authors)
DOI
10.1159/000345366

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Ghrelin, published as a controlled clinical trial.

The aims of the present study were to establish the incidence of ghrelin- and obestatin-immunoreactive cells in a comprehensive panel of human neuroendocrine tumors (NETs) and to investigate if blood obestatin concentrations are influenced during a standardized meal stimulation test in healthy individuals and patients with NETs.

Why It Was Studied

Ghrelin and obestatin are derived from the same peptide hormone precursor and are mainly produced by the gastric mucosa.

Ghrelin is involved in many biological processes, whereas the physiological function of obestatin needs further investigation.

Who Took Part

The study group was 6 individuals.

PubMed indexes the participants as young adults, adults and middle-aged adults.

Concentrations of obestatin in blood were measured during a meal test in 6 healthy individuals and 5 patients with pancreatic NETs.

How the Study Was Run

The expression of ghrelin and obestatin was investigated in NETs (n = 149) and other endocrine-related disorders (n = 3) using immunohistochemistry with specific polyclonal antibodies.

Coexpression of the peptides was evaluated by double immunofluorescence.

What Was Measured

PubMed files the paper under topics including Dietary Carbohydrates, Eating, Ghrelin, Immunohistochemistry, Neuroendocrine Tumors and Stomach Neoplasms.

What This Means in Plain Language

This is a controlled clinical trial of Ghrelin in 6 individuals.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Neuroendocrinology), a journal based in Switzerland.

More context: the Ghrelin compound page, all human trials.

Our Notes on the Compound

Ghrelin: A 28-amino-acid stomach hormone that signals hunger and triggers growth hormone release; studied in human trials as an infusion.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.